CEACAM1 and lymphoma: Lymphoma cells with high CEACAM1 expression were found to be more sensitive to ibrutinib than those with low expression levels (Fig. 3h), except for MAVER-1 cells, which had high CEACAM1 expression but were resistant to ibrutinib (see Discussion).